On the public citation graph

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit PCNSL Patients – The Multicenter MARTA Study

https://doi.org/10.2139/ssrn.4590911
0 signed · 26 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.ejca.2010.01.012openalex-extracted
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients
inferredcites →https://doi.org/10.1016/s0959-8049(01)00448-8openalex-extracted
Quality of life research within the EORTC—the EORTC QLQ-C30
inferredcites →https://doi.org/10.1016/s2352-3026(15)00074-5openalex-extracted
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
inferredcites →https://doi.org/10.1016/s2352-3026(16)00036-3openalex-extracted
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
inferredcites →https://doi.org/10.1016/s2352-3026(17)30174-6openalex-extracted
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
inferredcites →https://doi.org/10.1038/bmt.2017.101openalex-extracted
High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom
inferredcites →https://doi.org/10.1038/bmt.2017.23openalex-extracted
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study
inferredcites →https://doi.org/10.1038/leu.2016.334openalex-extracted
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
inferredcites →https://doi.org/10.1093/annonc/mdl464openalex-extracted
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
inferredcites →https://doi.org/10.1093/annonc/mdv076openalex-extracted
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
inferredcites →https://doi.org/10.1093/neuonc/noac196openalex-extracted
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
inferredcites →https://doi.org/10.1093/neuonc/nox187openalex-extracted
The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades
inferredcites →https://doi.org/10.1111/bjh.14073openalex-extracted
Trends in primary central nervous system lymphoma incidence and survival in the U.S.
inferredcites →https://doi.org/10.1111/bjh.16451openalex-extracted
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice
inferredcites →https://doi.org/10.1111/bjh.17799openalex-extracted
Advances in treatment of elderly primary central nervous system lymphoma
inferredcites →https://doi.org/10.1182/blood-2022-171733openalex-extracted
Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
inferredcites →https://doi.org/10.1182/bloodadvances.2020002064openalex-extracted
High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study
inferredcites →https://doi.org/10.1186/s12885-016-2311-4openalex-extracted
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)
inferredcites →https://doi.org/10.1186/s12885-019-5473-zopenalex-extracted
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
inferredcites →https://doi.org/10.1186/s12885-023-11193-7openalex-extracted
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial
inferredcites →https://doi.org/10.1200/jco.18.00306openalex-extracted
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study
inferredcites →https://doi.org/10.1200/jco.2005.13.524openalex-extracted
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
inferredcites →https://doi.org/10.1200/jco.2006.08.2941openalex-extracted
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
inferredcites →https://doi.org/10.1212/wnl.0000000000008900openalex-extracted
Management and outcome of primary CNS lymphoma in the modern era
inferredcites →https://doi.org/10.3324/haematol.2020.247536openalex-extracted
Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
inferredcites →https://doi.org/10.3390/cancers13174268openalex-extracted
Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.